Nov. 24: Germany to impose tax on Chinese e-commerce parcels
Germany will implement a new tax policy targeting cross-border e-commerce from China starting Nov. 24, levying a uniform 23% value-added tax on all e-commerce parcels and abolishing the previous minimum tax exemption threshold. This is expected to raise the average selling price of Chinese goods in the German market by 23%, directly affecting the market competitiveness of Chinese cross-border sellers.
Nov. 24: China’s central bank to issue bills in Hong Kong
The People’s Bank of China will conduct tenders through the Hong Kong Monetary Authority’s Central Moneymarkets Unit bond bidding platform to issue the eighth and ninth tranches of central bank bills for 2025. The eighth tranche will be 300 billion yuan ($42 billion), and the ninth tranche 150 billion yuan.
Nov. 26: U.K. chancellor to unveil annual budget
U.K. Chancellor of the Exchequer Rachel Reeves will announce the annual budget, a crucial fiscal plan for the Labour government. Economists expect that the U.K. may need to raise taxes or cut spending by up to 51 billion pounds ($67 billion) to fill a gap in public finances and rebuild its fiscal buffer, which is currently less than 10 billion pounds.
Nov. 26: HKEX to halt trading of Starcoin Group
Trading in the shares of Hong Kong-listed crypto-concept firm Starcoin will be halted by order of Hong Kong Exchanges and Clearing Ltd. The exchange questioned the company’s ability to meet continuing listing requirements.
Nov. 27: Guangzhou Futures Exchange to list palladium futures
Palladium futures contracts will be listed for trading on the Guangzhou Futures Exchange starting Nov. 27. On the first day of trading, the margin requirement will be 9% of the contract value, with a daily price fluctuation limit of 14% from the initial listing price. The trading fee will be 0.01% of the transaction value.
Nov. 28: HKEX to launch biotech index futures
Hong Kong stock exchange will launch Hang Seng Biotechnology Index futures, with trading to begin on Nov. 28. The contracts, based on the Hang Seng Biotechnology Index, are designed to provide investors with a precise risk management tool for a fast-growing sector and will complement the exchange’s existing biotech-related products.
